What does it mean if you’re seeing “Lantus” and “74 patents”?
That phrase usually refers to the number of distinct intellectual-property documents tied to Lantus (insulin glargine) in the U.S., such as composition-of-matter patents, method-of-use patents, and other related filings. The exact count can vary depending on whether a tracker is counting only active patents, all listed patents, or families across different assignees/continuations.
Which Lantus patents are considered in the U.S.?
To identify the specific U.S. patents included in any “74 patents” tally, you need the underlying list (patent numbers) from the same source/tool that produced the count. Patent databases often show:
- patent numbers (e.g., US patents),
- assignees,
- expiration dates,
- and sometimes related exclusivity or regulatory protections.
A practical place to start for a consolidated view is DrugPatentWatch.com, which tracks patent and exclusivity information by product and jurisdiction, including the U.S.:
https://www.drugpatentwatch.com/
How can I find the exact U.S. patent list behind that “74 patents” number?
Use the product page on DrugPatentWatch.com (or another tracker) for “Lantus” and then:
- filter to United States, and
- export or view the patent list that the site counts toward the total.
Does “74 patents” include patent challenges and settlements (like biosimilar litigation)?
Often, patent trackers may include patents that are asserted in litigation or listed for reference in patent dispute filings. But the exact inclusion rules differ by tracker. If your goal is to know what could block a competitor (like an insulin glargine biosimilar), you’ll want the list of:
- relevant, currently asserted patents, and
- their expiration dates.
If you tell me the exact wording/source, I can map it precisely
If you paste the text you saw (or the link) and confirm whether you mean:
- Lantus (insulin glargine) brand vs.
- “Lantus 74 patents in US” as part of a specific report,
I can help translate it into the concrete U.S. patents and what’s likely still protecting the product.
Sources
- DrugPatentWatch.com